Retinal Stem Cell Consortium
NSCI has created a research consortium to generate stem cell-based therapies to treat blinding retinal disease. The Retinal Stem Cell Consortium (RSSC) consists of leading stem cell scientists, retinal researchers, ophthalmologists and representatives of biotechnology companies from around the world working to create a seamless pathway from the laboratory to the clinic.
The RSSC targets diseases with great impact on patients, families and our economy. One in five people over age 75 suffers from Age-Related Macular Degeneration, which is the leading cause of blindness in the US. Our research harnesses stem cells to generate therapies for Macular Degeneration, Retinitis Pigmentosa, Diabetic Retinopathy, retinoblastoma, and choroidal melanoma. Our approaches include the activation of resident retinal stem cells to stimulate repair, generating stem cells for replacement of damaged retina, and the use of stem cells to model retinal disease for drug discovery.
The RSSC brings scientists together to solve the complex and multi-faceted application of stem cell research to blinding retinal disease.